24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Trametinib
Related studies linked through entity extraction aliases.
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
- Status
- RECRUITING
- Phase
- PHASE2
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
- Status
- RECRUITING
- Phase
- PHASE2
Pediatric Long-Term Follow-up and Rollover Study
- Status
- RECRUITING
- Phase
- PHASE4
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Molecular Profiling of Advanced Soft-tissue Sarcomas
- Status
- COMPLETED
- Phase
- PHASE3
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
- Status
- COMPLETED
- Phase
- PHASE3